Read by QxMD icon Read

Current Behavioral Neuroscience Reports

Marc J Dubin, Conor Liston, Michael A Avissar, Irena Llieva, Faith M Gunning
PURPOSE OF REVIEW: First, we will identify candidate predictive biomarkers of antidepressant response of TMS based on the neuroimaging literature. Next, we will review the effects of TMS on networks involved in depression. Finally, we will discuss ways in which our current understanding of network engagement by TMS may be used to optimize its antidepressant effect. RECENT FINDINGS: The past few years has seen significant interest in the antidepressant mechanisms of TMS...
March 2017: Current Behavioral Neuroscience Reports
Lois W Choi-Kain, Ellen F Finch, Sara R Masland, James A Jenkins, Brandon T Unruh
PURPOSE OF THE REVIEW: This review summarizes advances in treatments for adults with borderline personality disorder (BPD) in the last 5 years. RECENT FINDINGS: Evidence-based advances in the treatment of BPD include a delineation of generalist models of care in contrast to specialist treatments, identification of essential effective elements of dialectical behavioral therapy (DBT), and the adaptation of DBT treatment to manage post-traumatic stress disorder (PTSD) and BPD...
2017: Current Behavioral Neuroscience Reports
Stephanie J Temme, Brady J Maher, Kimberly M Christian
PURPOSE OF REVIEW: Induced pluripotent stem cells (iPSCs) can be generated from human patient tissue samples, differentiated into any somatic cell type, and studied under controlled culture conditions. We review how iPSCs are used to investigate genetic factors and biological mechanisms underlying psychiatric disorders, and considerations for synthesizing data across studies. RECENT FINDINGS: Results from patient specific-iPSC studies often reveal cellular phenotypes consistent with postmortem and brain imaging studies...
December 2016: Current Behavioral Neuroscience Reports
Alexandra K Gold, Rebecca E Montana, Louisa G Sylvia, Andrew A Nierenberg, Thilo Deckersbach
PURPOSE OF REVIEW: Cognitive impairments and biases, which are prevalent in patients with mood and anxiety disorders, can affect quality of life and functioning. Traditional treatments are only insufficiently addressing these impairments and biases. We review the cognitive impairments and biases present in these disorders as well as treatments targeting these domains. RECENT FINDINGS: Interventions aimed at improving cognitive impairments and biases may help improve cognitive deficits and overall functioning in patients with mood and anxiety disorders...
December 2016: Current Behavioral Neuroscience Reports
Kelly M Bakulski, Alycia Halladay, Valerie W Hu, Jonathan Mill, M Daniele Fallin
PURPOSE OF REVIEW: Evidence has linked neuropsychiatric disorders with epigenetic marks as either a biomarker of disease, biomarker of exposure, or mechanism of disease processes. Neuropsychiatric epidemiologic studies using either target brain tissue or surrogate blood tissue each have methodological challenges and distinct advantages. RECENT FINDINGS: Brain tissue studies are challenged by small sample sizes of cases and controls, incomplete phenotyping, post-mortem timing, and cellular heterogeneity, but the use of a primary disease relevant tissue is critical...
September 2016: Current Behavioral Neuroscience Reports
Anna R Docherty, Arden A Moscati, Ayman H Fanous
PURPOSE OF REVIEW: The following review provides some description of the movement in cross-disorder psychiatric genomics toward addressing both comorbidity and polygenicity. RECENT FINDINGS: We attempt to show how dimensional approaches to the phenotype have led to further addressing the problem of comorbidity of psychiatric diagnoses. And we also attempt to show how a dimensional approach to the genome, with different statistical methods from traditional genome-wide association analyses, has begun to resolve the problem of massive polygenicity...
September 2016: Current Behavioral Neuroscience Reports
Katherine H Frost, Gregory P Strauss
PURPOSE OF REVIEW: Anhedonia, traditionally defined as a diminished capacity to experience pleasure, has long been considered a core symptom of schizophrenia. However, recent research calls into question whether individuals with schizophrenia are truly anhedonic, suggesting intact subjective and neurophysiological response to rewarding stimuli in-the-moment. Despite a presumably intact capacity to experience pleasure, people with schizophrenia still engage in fewer reward-seeking behaviors...
September 2016: Current Behavioral Neuroscience Reports
Julia Vakhrusheva, Brielle Marino, T Scott Stroup, David Kimhy
Schizophrenia is characterized by extensive neurocognitive deficits, which are linked to greater disability, poorer functional outcome, and have been suggested to impact daily functioning more than clinical symptoms. Aerobic exercise (AE) has emerged as a potential intervention. This review examines the impact of AE on brain structure and function along with neurocognitive performance in individuals with schizophrenia. Preliminary evidence indicates that AE can increase hippocampal volume and cortical thickness, in addition to exerting a neuroprotective effect against hippocampal volume decrease and cortical thinning...
June 2016: Current Behavioral Neuroscience Reports
Amanda Crider, Anilkumar Pillai
Social interaction and communication are complex behavioral paradigms involving many components. Many different neurotransmitters, hormones, sensory inputs, and brain regions are involved in the act of social engagement and verbal or nonverbal communication. Autism Spectrum Disorder (ASD) and schizophrenia are two neurodevelopmental disorders that have social and language deficits as hallmark symptoms, but show very different etiologies. The output of social dysfunction is common to both ASD and schizophrenia, but this likely arises from very different pathophysiological means...
June 2016: Current Behavioral Neuroscience Reports
Dawn F Ionescu, George I Papakostas
Traditional antidepressant medications generally take weeks-to-months to achieve effect. However, the breakthrough finding of ketamine's rapidly acting antidepressant properties has inspired a decade-and-a-half of progress towards the identification of treatments that work quickly-within hours-to-days. This paradigm-shift in the discovery of antidepressant therapies has significantly changed the current landscape of antidepressant drug development. Building on this, the current review briefly highlights the recent trends in research towards identifying rapidly-acting antidepressants...
June 2016: Current Behavioral Neuroscience Reports
Bianca P Acevedo, Sarah Pospos, Helen Lavretsky
OBJECTIVES: Meditation has been shown to have physical, cognitive, and psychological health benefits that can be used to promote healthy aging. However, the common and specific mechanisms of response remain elusive due to the diverse nature of mind-body practices. METHODS: In this review, we aim to compare the neural circuits implicated in focused-attention meditative practices that focus on present-moment awareness to those involved in active-type meditative practices (e...
2016: Current Behavioral Neuroscience Reports
L S Morris, V Voon
Cognitive constructs provide conceptual frameworks for transpathological characterization and improved phenotyping of apparently disparate psychiatric groups. This dimensional approach can be applied to the examination of individuals with behavioral addictions, for example, towards gambling, video-games, the internet, food, and sex, allowing operationalization of core deficits. We use this approach to review constructs such as impulsivity, compulsivity, and attention regulation, which may be most relevant, applicable, and successful for the understanding and subsequent treatment of the addictions...
2016: Current Behavioral Neuroscience Reports
Joey A Contreras, Joaquín Goñi, Shannon L Risacher, Olaf Sporns, Andrew J Saykin
The human connectome refers to a comprehensive description of the brain's structural and functional connections in terms of brain networks. As the field of brain connectomics has developed, data acquisition, subsequent processing and modeling, and ultimately the representation of the connectome have become better defined and integrated with network science approaches. In this way, the human connectome has provided a way to elucidate key features of not only the healthy brain but also diseased brains. The field has quickly evolved, offering insights into network disruptions that are characteristic for specific neurodegenerative disorders...
December 2015: Current Behavioral Neuroscience Reports
Julie A Dumas
The idea that our cognitive abilities change with age has support from empirical research as well as from anecdotal reports. Cognition has many component processes, some of which are impaired by normal aging like attention and memory as a result of changes in perceptual systems or speed of processing. Other cognitive domains improve in functioning as aging continues such as wisdom and some kinds of decision making. Many years of research in the psychology of cognitive aging has described patterns of age-related changes in cognitive processes with older adults performing worse than younger adults on tests of attention, working memory and episodic memory and better on tests of general knowledge...
December 1, 2015: Current Behavioral Neuroscience Reports
Minkyung Park, Mark J Niciu, Carlos A Zarate
All currently approved antidepressant medications for major depressive disorder (MDD) and bipolar disorder act primarily on the monoaminergic system and have varying affinities for serotonergic, norepinephrine-ergic, and/or dopaminergic receptors. Unfortunately, these drugs are only effective in approximately two-thirds of patients. Glutamate is the major excitatory neurotransmitter in the central nervous system, and the glutamatergic system has been implicated in the pathophysiology of MDD. Here, we review the putative involvement of the glutamate receptor subtypes-N-methyl-D-aspartate (NMDA), α-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA), kainate, and the group I, II, and III metabotropic glutamate receptors (mGluRs)-in the development of novel and more effective treatments for MDD as well as preclinical and clinical trials of drugs targeting these receptors...
December 2015: Current Behavioral Neuroscience Reports
Sara Costi, Nicholas T Van Dam, James W Murrough
Major Depressive Disorder (MDD) is a leading cause of disability worldwide. Despite a plethora of established treatments, less than one-third of individuals with MDD achieve stable remission of symptoms. Given limited efficacy and significant lag time to onset of therapeutic action among conventional antidepressants, interest has shifted to treatments that act outside of the monoamine neurotransmitter systems (e.g., serotonin, norepinephrine, and dopamine). Preclinical and clinical research on the glutamate system has been particularly promising in this regard...
December 2015: Current Behavioral Neuroscience Reports
Mitra Heshmati, Scott J Russo
Anhedonia, or the loss of pleasure in previously rewarding stimuli, is a core symptom of major depressive disorder that may reflect an underlying dysregulation in reward processing. The mesolimbic dopamine circuit, also known as the brain's reward circuit, is integral to processing the rewarding salience of stimuli to guide actions. Manifestation of anhedonia and associated depression symptoms like feelings of sadness, changes in appetite, and psychomotor effects, may reflect changes in the brain reward circuitry as a common underlying disease process...
September 2015: Current Behavioral Neuroscience Reports
Ariel Schvarcz, Carrie E Bearden
The debilitating nature of schizophrenia necessitates early detection of individuals at clinical high-risk (CHR) in order to facilitate early intervention. In particular, comparisons between those who develop fully psychotic features (CHR+) and those who do not (CHR-) offer the opportunity to reveal distinct risk factors for psychosis, as well as possible intervention target points. Recent studies have investigated baseline clinical, neurocognitive, neuroanatomic, neurohormonal, and psychophysiological predictors of outcome; premorbid social dysfunction, deficits in neurocognitive performance, neuroanatomic changes, and hypothalamic-pituitary-adrenal (HPA) axis dysfunction have been implicated in psychosis emergence...
June 2015: Current Behavioral Neuroscience Reports
Pamela DeRosse, Katherine H Karlsgodt
The notion that psychosis may exist on a continuum with normal experience has been proposed in multiple forms throughout the history of psychiatry. However, in recent years there has been an exponential increase in efforts aimed at elucidating what has been termed the 'psychosis continuum'. The present review seeks to summarize some of the more basic characteristics of this continuum and to present some of the recent findings that provide support for its validity. While there is still considerable work to be done, the emerging data holds considerable promise for advancing our understanding of both risk and resilience to psychiatric disorders characterized by psychosis...
May 1, 2015: Current Behavioral Neuroscience Reports
Brandon M Hager, Matcheri S Keshavan
BACKGROUND: Biomarkers provide clinicians with a predictable model for the diagnosis, treatment and follow-up of medical ailments. Psychiatry has lagged behind other areas of medicine in the identification of biomarkers for clinical diagnosis and treatment. In this review, we investigated the current state of neuroimaging as it pertains to biomarkers for psychosis. METHODS: We reviewed systematic reviews and meta-analyses of the structural (sMRI), functional (fMRI), diffusion-tensor (DTI), Positron emission tomography (PET) and spectroscopy (MRS) studies of subjects at-risk or those with an established schizophrenic illness...
March 6, 2015: Current Behavioral Neuroscience Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"